Final SVR24 Data From the Phase 3 C-Edge Treatment-Naïve Study of Elbasvir (EBR)/Grazoprevir (GZR) in Patients with Chronic HCV Genotype 1, 4 or 6 Infection
Stefan Zeuzem(Goethe University Frankfurt), Eléonora De Martin, Joan R. Butterton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul J. Pockros(Scripps Clinic), Mark J. DiNubile(Io Therapeutics (United States)), Yuzhou Zhao(Capital Medical University), Ziv Ben Ari, D C Brown, Janice Wahl, K.R. Reddy, R. Ghalib, Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Emily Barr(University at Buffalo, State University of New York)
Cited by 1
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k